A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation.
Muruato AE, Fontes-Garfias CR, Ren P, Garcia-Blanco MA, Menachery VD, Xie X, Shi PY. · 2020
Read A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. by Muruato AE, Fontes-Garfias CR, Ren P, Garcia-Blanco MA, Menachery VD, Xie X, Shi PY. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7426916.txt.
Introduction
Muruato and co-authors build a fast test for neutralizing antibodies against SARS-CoV-2. Such antibodies block the virus, and virus neutralization is the gold standard for judging them. A high-throughput test was needed for diagnosis, plasma therapy, and vaccine work.
Their fluorescence-based test detects neutralizing antibodies in samples from COVID-19 patients. Its results match the plaque reduction test, the standard lab method. The test stayed specific: samples with other viral, bacterial, or parasitic infections did not cross-react. Because the method is rapid and can scale, it can screen many people for antibody protection. That kind of screening helps communities judge when reopening is safe.
Catalog record
| CREATOR | Muruato AE, Fontes-Garfias CR, Ren P, Garcia-Blanco MA, Menachery VD, Xie X, Shi PY. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 26 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation By Antonio E. Muruato, Camila R. Fontes-Garfias, Ping Ren, Mariano A. Garcia-Blanco, Vineet D. Menachery, Xuping Xie, Pei-Yong Shi Published in: Nature Communications DOI: 10.1038/s41467-020-17892-0 ABSTRACT Virus neutralization remains the gold standard for determining antibody efficacy. Therefore, a high-throughput assay to measure SARS-CoV-2 neutralizing antibodies is urgently needed for COVID-19 serodiagnosis, convalescent plasma therapy, and vaccine development. Here, we report on a fluorescence-based SARS-CoV-2 neutralization assay that detects SARS-CoV-2 neutralizing antibodies in COVID-19 patient specimens and yields comparable results to plaque reduction neutralizing assay, the gold standard of serological testing. The fluorescence-based neutralization assay is specific to measure COVID-19 neutralizing antibodies without cross reacting with patient specimens with other viral, bacterial, or parasitic infections. Collectively, our approach offers a rapid platform that can be scaled to screen people for antibody protection from COVID-19, a key parameter necessary to safely reopen local communities. INTRODUCTION The ongoing coronavirus disease 2019 (COVID-19) pandemic is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first reported in Wuhan, China in late 20191,2. As of June 28, 2020, COVID-19 has caused 10.3 million confirmed infections and over 505,741 deaths worldwide (https://www.worldometers.info/coronavirus/). Many areas of the world have been in lockdown mode to curb the viral transmission, but the reality is that COVID-19 is here to stay until a safe and efficacious vaccine becomes available. The pandemic’s catastrophic economic impact is pushing governments to reopen their economies, and this creates a public health quandary. At this time, our only option is to minimize viral transmission through social distancing and contact tracing, which relies on the diagnosis of viral RNA through reverse transcription polymerase chain reaction (RT-PCR) (https://www.fda.gov/media/134922/download). Proper public health policy would be greatly enhanced if we had a reliable and facile assay to measure the immune protection among COVID-19 recovered patients. Coronavirus infections typically induce neutralizing antibody responses3. The seroconversion rates in COVID-19 patients are 50% and 100% on day 7 and 14 post symptom onset, respectively4. Given the unknown scale of asymptomatic infections, there is a pressing need for serological diagnosis to determine the real number of infections. Such information is essential for defining the case-fatality rate and for making the policy on the scale and duration of social lockdowns. The serological assays are also required to identify donors with high-neutralizing titers for convalescent plasma for therapy, and to define correlates of protection from SARS-CoV-2. While viral RNA-based testing for acute infection is the current standard, surveying antibody protection is a necessary part of any return to social normality. For serodiagnosis, several COVID-19 assay platforms have achieved FDA emergency use authorizations (EUA), including ELISA5 (https://www.fda.gov/media/137029/download), lateral flow immunoassay (https://www.fda.gov/media/136625/download), and Microsphere Immunoassay (https://www.fda.gov/media/137541/download). These assays measure antibody binding to SARS-CoV-2 spike protein. Since not all spike-binding antibodies can block viral infection, these platforms do not functionally measure antibody inhibition of SARS-CoV-2 infection. An ideal serological assay should measure neutralizing antibody levels, which should predict protection from reinfection. Conventionally, neutralizing antibodies are measured by plaque reduction neutralization test (PRNT). Although PRNT and ELISA results generally corelate with each other, particularly when the receptor-binding domain of SARS-CoV-2 spike protein is used as an ELISA antigen (https://www.genscript.com/cpass-sars-cov-2-neutralization-antibody-detection-Kit.html)6,7, PRNT remains the gold standard for serological testing and determining immune protection8,9. However, due to its low throughput, PRNT is not practical for large scale serodiagnosis and vaccine evaluation. This is a major gap for COVID-19 surveillance and vaccine development. Here, we report a fluorescence-based high-throughput neutralization assay that detects SARS-CoV-2 neutralizing antibodies in patient specimens and yields equivalent results to the gold standard plaque reduction neutralizing assay. RESULTS A high-throughput fluorescence-based neutralization assay To fill in the gap for COVID-19 serodiagnosis and vaccine evaluation, we developed a fluorescence-based assay that rapidly and reliably measures neutralization of a reporter SARS-CoV-2 by antibodies from patient specimens. The assay was built on a stable mNeonGreen (mNG) SARS-CoV-2 where the mNG gene was engineered at the ORF7 of the viral genome (Fig. 1a)10. The complete sequence of mNG SARS-CoV-2 is described in Supplementary Fig. 1. Figure 1b depicts the flowchart of the reporter neutralization assay in a 96-well format. The assay protocol is detailed in Supplementary Methods. Briefly, patient sera were serially diluted and incubated with the reporter virus. After incubation at 37°C for 1 h, Vero CC-81 cells (pre-seeded in a 96-well plate) were infected with the virus/serum mixtures at a multiplicity of infection (MOI) of 0.5. At 16 h post-infection, the mNG-positive cells were quantitated using a high-content imaging reader (Fig. 1b). It should be noted that Vero CC-81 cells, not Vero E6 cells, were chosen for the mNG assay to enable accurate quantification of fluorescent cells. Sixty COVID-19 serum specimens from RT-PCR-confirmed patients and 60 non-COVID-19 serum samples (archived before COVID-19 emergence) were analyzed using the reporter virus. For some COVID-19-positive specimens, the sample collection days post viral RT-PCR positive were available and are indicated in Table 1. After reporter viral infection, the cells turned green in the absence of serum (Fig. 1c, bottom panel); in contrast, incubation of the reporter virus with COVID-19 patient serum decreased the number of fluorescent cells (top panel). A dose–response curve was obtained between the number of fluorescent cells and the fold of serum dilution (Fig. 1d and Supplementary Fig. 2), which allowed for determination of the dilution fold that neutralized 50% of fluorescent cells (NT50). The reporter assay rapidly diagnosed 120 specimens within 24 h: all 60 COVID-19 sera (specimens 1–60) showed positive NT50 of 35 to 5711, and all 60 non-COVID-19 sera (specimens 61–120) showed negative NT50 of <20 (Table 1).Fig. 1A high-throughput neutralizing antibody assay for COVID-19 diagnosis.a Diagram of the cDNA constructs of wild-type (WT) SARS-CoV-2 (top panel) and mNG SARS-CoV-2 (bottom panel). The nucleotide positions of viral genome where mNG is engineered are indicated. b Assay flowchart. mNG SARS-CoV-2 was neutralized with COVID-19 patient sera. Vero CCL-81 cells were infected with the reporter virus/serum mixture with an MOI of 0.5. The fluorescence of infected cells was quantified to estimate the NT50 value for each serum. c Representative images of reporter virus-infected Vero CCL-81 cells. Images for a positive neutralizing serum (top panel) and no serum control (bottom panel) are presented. Scale bar, 100 μm. d Neutralization curves. Representative neutralization curves are presented for three positive sera and one negative sera. The means and standard deviations from two independent experiments are presented. e Correlation analysis of NT50 values between the reporter virus and PRNT assays. The Pearson correlation efficiency R2 and p-value (two-tailed) are indicated.Table 1Comparison of neutralization titers of patient sera analyzed by reporter assay and plaque reduction assay.aSerum IDbcPRNT50cmNG-NT50aSerum IDbcPRNT50cmNG-NT501 (d1)<203532 (d9)6407622 (d5)<203833 (d8)3208463 (d4)<205034 (d14)8008734 (d5)405835 (d16)16008745 (d5)206636 (d17)3209006 (d6)807437 (d9)8009027 (d8)807738 (d15)8009498 (d4)808539 (d15)4009589 (d5)808540 (d18)800101610 (d1)809541 (d28)1280107211 (d6)809642 (d12)800113912 (NA)1609643 (d13)800114513 (d6)4011144 (d14)800121014 (d6)4011445 (d31)640121315 (d1)8011546 (d8)800141916 (d9)16012047 (d14)1600159017 (d11)8013248 (d21)1600161718 (d8)8020049 (d12)1600214819 (NA)16026150 (NA)2560222520 (d5)16031851 (d20)1600228721 (d32)32032952 (d8)1600236222 (d14)16036553 (d12)1600246323 (d12)16036654 (d18)1600255424 (d37)32045655 (d16)1600283225 (NA)32047456 (d15)3200322826 (d47)32052557 (d31)3200425727 (d12)64061758 (NA)3200515228 (d9)32064959 (d8)3200566229 (d10)64068160 (NA)3200571130 (d27)32072161–120<20<2031 (d9)640727aA total of 120 patient sera were analyzed, including 60 specimens from RT-PCR-confirmed patients (specimens 1–60) and 60 negative specimens (specimens 61–120) that were collected before COVID-19 pandemic (prepandemic).bSample collection days post after RT-PCR positive test are indicated